AbbVie Inc. (ABBV) has a MoatMap StockRank of 83/100 based on Quality (55/100), Value (48/100), and Momentum (64/100) factor scores. The current signal is STRONG BUY. AbbVie is a high-quality pharma giant with strong pricing power, but it is a consumer of manufacturing capacity rather than a pure-play CDMO beneficiary, and faces ongoing biosimilar erosion for Humira.
AbbVie Inc. is a global biopharmaceutical company focusing on the research, development, manufacturing, and sales of innovative therapies across immunology, oncology, neuroscience, and other specialty areas. It possesses a robust product pipeline and a portfolio of blockbuster drugs, such as Humira and Skyrizi, driving significant revenue and market share. AbbVie is a leading pharmaceutical innovator known for its strong R&D capabilities and strategic acquisitions.
| Price | $223.42 |
| Market Cap | $364.6B |
| P/E (TTM) | 109.73 |
| P/E (Forward) | 13.84 |
| Price/Book | -59.71 |
| Return on Invested Capital | 10.5% |
| Gross Margin | 72.0% |
| Operating Margin | 32.2% |
| Revenue Growth | 12.4% |
| Dividend Yield | 3.1% |
| Free Cash Flow | $20.8B |
AbbVie Inc. operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).